20:26 , Jul 20, 2018 |  BioCentury  |  Emerging Company Profile

Selective Regeneration

Surrozen Inc. is making tunable bispecific antibodies molecules it believes can overcome a major hurdle that has prevented other companies from tapping the Wnt pathway for regenerative medicine: namely, the inability to drug specific members...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

AEM-28: Phase Ib/IIa data

LipimetiX Development LLC and Capstone reported pooled data from a double-blind, placebo-controlled, Australian Phase Ia trial and a double-blind, placebo-controlled, Australian Phase Ib/IIa trial in patients with refractory hypercholesterolemia and healthy volunteers with elevated fasting...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

AEM-28: Phase Ib/IIa ongoing

LipimetiX Development LLC began the multiple ascending-dose portion of a double-blind, placebo-controlled, Australian Phase Ib/IIa trial of IV AEM-28 in 15 patients with refractory hypercholesterolemia. Per protocol, the second portion began after the single ascending-dose...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

AEM-28: Phase Ia started

LipimetiX Development LLC began a double-blind, placebo-controlled, Australian Phase Ia trial to evaluate single and multiple ascending-doses of IV AEM-28 in about 36 healthy volunteers with elevated cholesterol. LipimetiX Development is a JV between Capstone...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Clinical News

TVC Imaging System: Clinical trial started

Infraredx began the international Lipid-Rich Plaque (LRP) study to evaluate the TVC Imaging System in about 9,000 patients presenting for coronary angiography in whom IVUS and/or NIRS evaluation is planned or could be used as...
07:00 , Jun 7, 2010 |  BioCentury  |  Emerging Company Profile

LipimetiX: Aping APOE

LipimetiX LLC is hoping to bypass defective LDL receptors in the livers of patients with heritable hyperlipidemia with its mimetics of apolipoprotein E, a protein that can target two additional hepatic receptors capable of clearing...
07:00 , Oct 26, 2009 |  BioCentury  |  Product Development

Breaking through the BBB

The idea of using the brain's own transport receptors to ferry drugs across the blood-brain barrier has been around for more than a decade. AngioChem Inc., one of a new generation of companies trying to...
08:00 , Mar 2, 2009 |  BioCentury  |  Finance

Genentech rebuts Roche pessimism

Genentech rebuts Roche pessimism Roche's criticism Genentech response Future pricing - increases assumed Genentech assumed portfolio-weighted average price increases of about 3.6% in 2009, trending down to about optimistic 2.3% by 2015...
08:00 , Feb 16, 2009 |  BioCentury  |  Finance

Roche finds Genentech inflated

Roche finds Genentech inflated Item Roche's view of the November model Future pricing Price increases assumed in the model are optimistic given the effect of policy initiatives that may be introduced by...
07:00 , Oct 20, 2008 |  BC Week In Review  |  Company News

Lorus, Zoticon Bioventures. deal

The parties added Central America to the territories covered under Zoticon's license to Virulizin from Lorus' GeneSense Technologies Inc. subsidiary. Also, Lorus received a $150,000 milestone payment from Zoticon's Zor Pharmaceuticals LLC subsidiary, triggered...